Metabolic acidosis is associated with poor outcomes in CKD. Because impaired renal ammonium excretion is important in the pathogenesis of acidosis, urine ammonium excretion might be a better and perhaps earlier acid-base indicator of risk than serum bicarbonate, particularly in patients without acidosis. We evaluated the association between baseline ammonium excretion and clinical outcomes in African American Study of Kidney Disease and Hypertension participants (n=1044). Median daily ammonium excretion was 19.5 (95% confidence interval [95% CI], 6.5 to 43.2) mEq. In Cox regression models (adjusted for demographics, measured GFR, proteinuria, body mass index, net endogenous acid production, and serum potassium and bicarbonate), hazard ratios of the composite outcome of death or dialysis were 1.46 (95% CI, 1.13 to 1.87) in the low tertile and 1.14 (95% CI, 0.89 to 1.46) in the middle tertile of daily ammonium excretion compared with the high tertile. Among participants without acidosis at baseline, the adjusted hazard ratio for those with ammonium excretion ,20 mEq/d was 1.36 (95% CI, 1.09 to 1.71) compared with those with ammonium excretion $20 mEq/d. Additionally, compared with participants in the high ammonium tertile, those in the low ammonium tertile had higher adjusted odds of incident acidosis at 1 year (adjusted odds ratio, 2.56; 95% CI, 1.04 to 6.27). In conclusion, low ammonium excretion is associated with death and renal failure in hypertensive kidney disease, even among those without acidosis. Low ammonium excretion could identify patients with CKD and normal bicarbonate levels who might benefit from alkali before acidosis develops.
In nondialysis-requiring CKD, the prevalence of metabolic acidosis, typically defined as serum total carbon dioxide (tCO 2 ) ,22 mEq/L, is approximately 15%. 1, 2 The prevalence increases with advancing CKD, from 7% in stage 2 to 37% in stage 4 CKD. 2 Some, but not all, observational studies identified low tCO 2 as a risk factor for GFR decline and mortality. [3] [4] [5] [6] [7] Differences in population characteristics and methodologic approaches may explain these discrepancies. Another possibility is that tCO 2 , although convenient and commonly measured in clinical practice and research settings, may not be the best acid-base indicator of risk.
Because urine ammonium (uNH 4 + ) excretion is critical for the maintenance of normal tCO 2 and reduced uNH 4 + excretion plays an important role in the development of metabolic acidosis in CKD, it may be an alternative and perhaps earlier indicator of risk than tCO 2 . Indeed, Vallet et al. found that lower uNH 4 + excretion was a risk factor for ESRD in .1000 patients with CKD in the NephroTest cohort. 8 However, they did not adjust for serum tCO 2 or nutritional indicators of acid-alkali content, such as protein intake or net endogenous acid production (NEAP), in their main analyses. Hence, it is uncertain whether uNH 4 + excretion has prognostic value above and beyond tCO 2 or if the excess risk of ESRD associated with low uNH 4 + is because of poor nutritional status. Nevertheless, this finding highlights the potential to use uNH 4 + measurements to identify at-risk individuals. This may be especially important for those with normal tCO 2 , who comprise the vast majority of patients with CKD. 1, 2 For instance, if low uNH 4 + were shown to be a risk factor for poor outcomes in patients with CKD and normal tCO 2 , it is plausible that base administration before acidosis ensues might prevent acidosisrelated complications in CKD. Thus, the main objective of this study was to determine if uNH 4 + excretion is associated with long-term clinical end points in CKD independent of serum tCO 2 , NEAP, GFR, and other potential confounders. Secondary objectives were to determine, in the subgroup of patients with CKD without acidosis, whether daily uNH 4 + excretion is associated with subsequent acidosis as well as clinical events.
RESULTS
We evaluated data from participants in the African American Study of Kidney Disease and Hypertension (AASK) Study. Table 1 presents baseline characteristics of the 1044 participants included in the main analyses. Daily uNH 4 + excretion was higher in men and those with higher body mass index (BMI), dietary protein intake, and NEAP. Measured GFR (mGFR) and tCO 2 were higher and serum potassium was lower in the highest uNH 4 + tertile. As expected, uNH 4 + excretion was lower with lower mGFR (Figure 1 ). Figure 2 presents unadjusted scatterplots between uNH 4 + and mGFR, tCO 2 , NEAP, and protein intake. Daily protein intake had a moderate correlation with uNH 4 + , mGFR and NEAP had low correlation with uNH 4 + , and tCO 2 did not correlate with uNH 4 + in the unadjusted analyses. Table 2 presents the adjusted multivariate linear regression results of the association between daily uNH 4 + excretion and key clinical factors. Sex (men), obesity, higher NEAP, higher mGFR, higher urine protein-to-creatinine ratio, and lower serum potassium were associated with higher uNH 4 + excretion. There was no association between serum tCO 2 and uNH 4 + after multivariate adjustment. Table 3 presents the number and incidence rates of death or ESRD events during follow-up in the entire cohort and according to uNH 4 + tertile. The number and incidence of events were higher with lower daily uNH 4 + excretion. Figure 3 presents the unadjusted composite outcome of death or ESRD by tertiles of baseline daily uNH 4 + excretion. Event-free survival was highest in the highest tertile of uNH 4 + excretion and lowest in the lowest tertile of uNH 4 + excretion. 4 + tertile compared with the highest uNH 4 + tertile, adjusted for model 1 variables). An additional sensitivity analysis using uNH 4 + indexed to body weight in mEq/kg per day as the independent variable showed similar results. Those in the lowest tertile of uNH 4 + in mEq/kg per day had higher risk of the composite outcome (HR, 1.51; 95% CI, 1.17 to 1.94) than those in the highest tertile. Compared with those in the upper tertile of uNH 4 + in mEq/kg per day, the HR for death or ESRD was 1.15 (95% CI, 0.90 to 1.47) for those in the middle tertile. Figure 5 shows the adjusted Cox model results in which participants were categorized into one of four groups according to serum tCO 2 and daily uNH 4 + excretion: (1) There was no additive (relative excess risk from interaction = 0.34; 95% CI, 20.41 to 1.09; P=0.38) or multiplicative interaction (ratio of HRs =1.13; 95% CI, 0.68 to 1.87; P=0.64) between tCO 2 and uNH 4 + with the death or ESRD composite outcome.
To evaluate the relationship between uNH 4 + and later development of acidosis, we determined the odds of acidosis at the 1-year follow-up visit by uNH 4 + tertile among participants without acidosis at baseline. Of the 1044 participants in the main analysis, 916 did not have acidosis at baseline. Of these, 866 participants had serum tCO 2 measured at 1 year; 287, 282, and 297 in the lowest, middle, and highest tertiles of uNH 4 + at baseline, respectively. At 1 year, 87 (10%) of these participants developed acidosis; 50 in the lowest, 22 in the middle, and 15 in the highest tertile of baseline uNH 4 + . After adjusting for randomized treatment assignment and baseline characteristics, those in the lowest tertile of uNH 4 + had significantly higher odds of acidosis than those in the highest tertile of uNH 4 + at 1 year (Table 6 ).
DISCUSSION
Renal ammonia (NH 3 ) production and consequent uNH 4 + excretion are critically important processes that help maintain acid-base homeostasis. The decline in uNH 4 + excretion that accompanies reduced GFR is a key contributing factor to the development of metabolic acidosis in CKD, which is associated with poor outcomes in this population. Since reduced uNH 4 + excretion precedes the development of metabolic acidosis in this setting, measurements of uNH 4 + excretion could be an indicator of risk, and perhaps a better indicator of risk, than tCO 2 . In this study of black patients with hypertensive CKD, we identified an association between lower daily uNH 4 + excretion and higher risk of death or ESRD independent of demographic factors, CKD severity factors, tCO 2 , and nutritional indicators of acid and alkali intake. The findings were similar when uNH 4 + excretion was indexed to body weight. Analyses of the individual outcomes found a relationship between uNH 4 + excretion and ESRD but not mortality, perhaps because of the greater number of ESRD events than death before ESRD events in the AASK cohort. Our results are consistent with those of a previous study that observed a higher risk of ESRD with lower uNH 4 + excretion. 8 Here, we show that this relationship is independent of serum tCO 2 and nutritional determinants of acid-base status. In addition, we show that among individuals without acidosis, uNH 4 + excretion ,20 mEq/d is associated with higher risk of death or ESRD (36%) than daily uNH 4 + excretion $20 mEq/d. Finally, we have quantitated the strength of the relationship between low uNH 4 + excretion and the risk of subsequent acidosis for the first time. Cumulatively, these data suggest that low daily uNH 4 + excretion has a prognostic value in CKD in terms of acidosis risk, as well as longterm clinical outcomes, irrespective of systemic tCO 2 and other factors. Incidence rate shows the total number of events per 1000 patient-yr. SBP, systolic BP; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; PCR, urine protein-to-creatinine ratio.
As expected, uNH 4 + directly correlated with mGFR and inversely correlated with serum potassium after multivariate adjustment. Obese participants had higher uNH 4 + excretion than nonobese participants, perhaps because of dietary factors or higher NEAP, as did men and those with proteinuria. Although renal acid excretion is thought to decline with aging, there was a trend toward higher uNH 4 + excretion in older AASK participants. Daily uNH 4 + also directly correlated with protein intake and NEAP after multivariate adjustment. Hence, it is plausible that the reason why low uNH 4 + is associated with poor outcomes in CKD is because of poor nutritional status. However, we adjusted for nutritional factors including NEAP and BMI in our analyses. Furthermore, if low uNH 4 + were the result of low acid intake from poor nutritional status, then it would be expected that uNH 4 + excretion would match dietary acid intake and acidbase balance would be relatively stable over time. However, those in the lowest uNH 4 + tertile had .2.5-fold higher odds of subsequent acidosis at 1 year compared with those in the highest tertile of uNH 4 + excretion. Hence, it is likely that participants with low uNH 4 + had impaired renal acid excretion rather than poor nutritional status, with consequent acid retention, higher risk of subsequent acidosis, and poor clinical outcomes. Nevertheless, the associations between uNH 4 + excretion and the clinical outcomes in this cohort of black patients with hypertensive CKD were independent of these important confounders.
The results of this study may have important implications for research and perhaps clinical practice. Clinical practice guidelines recommend correcting acidosis with chronic oral alkali to prevent bone demineralization and protein catabolism, and results from single-center studies also suggest that correcting acidosis may slow CKD progression. [9] [10] [11] Hence, patients with CKD and acidosis are commonly prescribed oral alkali. However, several lines of evidence from animal models of CKD and observational studies in humans suggest that alkaline therapy may be beneficial in patients with CKD without acidosis. 3, 5, 12 This notion is reinforced by findings from a single-center interventional study in patients with hypertensive stage 2 CKD and mean tCO 2 in the normal range (approximately 26 mEq/L). 13 In this study, individuals who received oral sodium bicarbonate had better renal function than a placebo group after 5 years, despite having similar GFR at baseline. Thus, oral alkaline therapy is a promising intervention in patients with CKD and normal tCO 2 . However, the vast majority of patients with CKD have normal tCO 2 , and administering alkali to these individuals may lead to overtreatment on a population level. 1, 2 The results from this and the NephroTest cohort suggest that uNH 4 + could be used to risk-stratify individuals with CKD without acidosis who might be more likely to benefit from alkali. Our results suggest that an uNH 4 + excretion threshold ,20 mEq/d could be used to risk-stratify individuals.
One of the mechanisms by which acidosis and subclinical acidosis is thought to contribute to GFR decline in CKD is via NH 3 -mediated activation of the alternative pathway of complement, ultimately leading to tubulointerstitial fibrosis. 14, 15 Thus, it might be expected that higher uNH 4 + excretion would predict CKD progression. However, we found an association between lower uNH 4 + excretion and higher risk of poor outcomes, particularly as it relates to renal function. Although these findings are seemingly contradictory to the hypothesis that NH 3 is a direct cause of renal injury, it is important to note that uNH 4 + excretion may not necessarily reflect tissue levels of NH 3 . For instance, low uNH 4 + excretion because of impaired NH 3 /NH 4 + transport could lead to high interstitial concentrations of NH 3 /NH 4 + and consequent intrarenal complement activation. It is more likely that low uNH 4 + excretion is simply an indicator of poor acid excretory capacity and kidney function. Thus, the results of this study do not necessarily contradict the notion that intrarenal NH 3 contributes to renal injury in CKD. Our study has several strengths. The AASK Study has a well characterized cohort with long-term follow-up and careful data collection. Furthermore, .95% of randomized participants were included in the main analyses. Second, GFR was measured by 125 iodine-iothalamate clearance in the AASK Study, which is important considering the strong relationship between renal function and uNH 4 + excretion. Third, carefully collected 24-hour urine samples were required before randomization. Notably, the median daily uNH 4 + excretion in the AASK cohort was 19.5 mEq, which is similar to the median daily value in the NephroTest cohort (18.5 mEq). 8 Like all observational studies, residual confounding remains possible. uNH 4 + was measured once at baseline, hence we were not able to assess variability of uNH 4 + excretion over time in this study. We evaluated black patients with hypertensive CKD, hence our findings may not be generalizable to other populations.
In summary, lower uNH 4 + excretion is a risk factor for acidosis and poor renal and survival outcomes among blacks with hypertensive CKD irrespective of important confounders, tCO 2 , and nutritional determinants of acid-base status. Similar findings were observed in another CKD cohort. 8 Hence, uNH 4 + excretion has prognostic value above and beyond tCO 2 . With accumulating interest in the potential use of alkaline therapy to slow CKD progression in patients without overt acidosis, the observation that lower daily uNH 4 + excretion in this setting signals a higher risk of death or ESRD suggests that uNH 4 + may better risk-stratify these individuals.
CONCISE METHODS

Study Participants
The details of the AASK Study have been published. [16] [17] [18] Briefly, black patients aged 18-70 years with hypertensive CKD (defined by an mGFR between 20 and 65 ml/min per 1.73 m 2 by renal clearance of 125 iodine-iothalamate and diastolic BP .95 mmHg) were eligible for the study. Key exclusion criteria included elevated fasting or random blood glucose, treatment for diabetes, and urine proteinto-creatinine ratio .2.5 g/g. Between April of 1995 and September of 1998, 1094 participants were randomized to ramipril, metoprolol, or amlodipine, and to one of two BP goals (usual mean arterial pressure goal of 102-107 mmHg or a low mean arterial pressure goal of #92 mmHg). At the end of the randomized trial phase, participants who did not reach ESRD were eligible to enroll in the nonrandomized AASK Cohort Study, during which BP was targeted to ,130/80 mmHg using ramipril or an angiotensin receptor blocker as the first-line therapy in all participants. Baseline (prerandomization) urine samples were available for 1057 4 + excretion was ,20 mEq or $20 mEq and whether serum tCO 2 was ,22 or $22 mEq/L. Those with daily uNH 4 + excretion $20 mEq and serum tCO 2 $22 mEq/L served as the reference. Additive interaction was evaluated by determining the relative excess risk from interaction with 95% CIs, and multiplicative interaction was evaluated by determining the ratio of HRs with 95% CIs. 21, 22 Logistic regression analyses (adjusted for demographic factors, randomized treatment assignment, and baseline mGFR, proteinuria, NEAP, serum potassium, and BMI) determined the odds of acidosis at 1 year among participants without acidosis at baseline by baseline uNH 4 + , using the highest tertile of uNH 4 + as the reference group. The analyses were performed using Stata 14 (StataCorp, College Station, TX). 
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